Scholarlink

Introduction <p>Over half of patients with Parkinson’s disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients’ health-related quality of life and cognitive abilities, these symptoms impact patients’ activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.</p> Methods <p>An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson’s correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.</p> Results <p>In this assessment (<i>n</i>&#xa0;=&#xa0;29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2–41.5; <i>p</i>&#xa0;=&#xa0;0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.</p> Conclusion <p>This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Modified Functional Status Questionnaire for Assessing Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月12日

查看全文
  • Virgilio G. H. Evidente,
  • Lambros Chrones,
  • Ratna Revankar,
  • Dilesh Doshi,
  • Victor Abler,
  • Nazia Rashid

摘要

Introduction

Over half of patients with Parkinson’s disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients’ health-related quality of life and cognitive abilities, these symptoms impact patients’ activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.

Methods

An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson’s correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.

Results

In this assessment (n = 29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2–41.5; p = 0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.

Conclusion

This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.